Constitutive activation of Notch2 signalling confers chemoresistance to neural stem cells via transactivation of fibroblast growth factor receptor-1.


Journal

Stem cell research
ISSN: 1876-7753
Titre abrégé: Stem Cell Res
Pays: England
ID NLM: 101316957

Informations de publication

Date de publication:
03 2019
Historique:
received: 10 07 2018
revised: 28 11 2018
accepted: 23 01 2019
pubmed: 15 2 2019
medline: 5 9 2019
entrez: 15 2 2019
Statut: ppublish

Résumé

Notch signalling regulates neural stem cell (NSC) proliferation, differentiation and survival for the correct development and functioning of the central nervous system. Overactive Notch2 signalling has been associated with poor prognosis of aggressive brain tumours, such as glioblastoma multiforme (GBM). We recently reported that constitutive expression of the Notch2 intracellular domain (N2ICD) enhances proliferation and gliogenesis in NSCs. Here, we investigated the mechanism by which Notch2 promotes resistance to apoptosis of NSCs to cytotoxic insults. We performed ex vivo studies using NSC cultures from transgenic mice constitutively expressing N2ICD. These NSCs expressed increased levels of pro-survival factors and lack an apoptotic response to the topoisomerase inhibitor etoposide, not showing neither mitochondrial damage nor caspase activation. Interestingly, Notch2 signalling also regulated chemoresistance of human GBM cells to etoposide. We also identified a signalling crosstalk with FGF signalling pathway involved in this resistance to apoptosis of NSCs. Aberrant Notch2 expression enhances fibroblast growth factor receptor-1 (FGFR1) activity to specifically target the AKT-GSK3 signalling pathway to block apoptosis. These results have implications for understanding molecular changes involved in both tumorigenesis and therapy resistance.

Identifiants

pubmed: 30763736
pii: S1873-5061(19)30020-0
doi: 10.1016/j.scr.2019.101390
pii:
doi:

Substances chimiques

Notch2 protein, mouse 0
Receptor, Notch2 0
Etoposide 6PLQ3CP4P3
Fgfr1 protein, mouse EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 1 EC 2.7.10.1
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

101390

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Mercedes Tomé (M)

Department of Biomedicine, Pharmazentrum, University of Basel, 4056 Basel, Switzerland. Electronic address: mercedes.tome@u-bordeaux.fr.

Jan Tchorz (J)

Department of Biomedicine, Pharmazentrum, University of Basel, 4056 Basel, Switzerland.

Martin Gassmann (M)

Department of Biomedicine, Pharmazentrum, University of Basel, 4056 Basel, Switzerland.

Bernhard Bettler (B)

Department of Biomedicine, Pharmazentrum, University of Basel, 4056 Basel, Switzerland. Electronic address: bernhard.bettler@unibas.ch.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH